Cellares Partners with Seoul National University Hospital to Automate Gene Therapy Manufacturing — Cellares Corporation

Event summary

Cellares and Seoul National University Hospital (SNUH) have launched a proof-of-concept to automate the manufacturing of gene-modified HSPC therapy for paroxysmal nocturnal hemoglobinuria (PNH) on Cellares’ Cell Shuttle platform.
The collaboration focuses on translating SNUH’s gene-modified HSPC manufacturing process to the Cell Shuttle, supporting a two-step transfection workflow using Cellares’ fully integrated electroporation module.
This marks Cellares’ second collaboration in Asia, expanding its network in the Asia-Pacific region and supporting SNUH’s program toward clinical development in the United States.
The goal is to establish a scalable manufacturing strategy for future U.S. clinical development, improving reliability and driving down manufacturing costs.

The big picture

Cellares’ collaboration with SNUH underscores the growing demand for automated, scalable manufacturing solutions in the gene therapy space. As gene-modified HSPC therapies become more complex, the ability to streamline production processes is critical for reducing costs and improving patient access. This partnership also highlights Cellares’ strategic expansion into the Asia-Pacific market, where demand for advanced manufacturing technologies is rising.

What we're watching

Technical Feasibility: Whether the Cell Shuttle platform can successfully automate SNUH’s complex manufacturing process for gene-modified HSPC therapy.
Regulatory Pathway: The pace at which SNUH’s PNH program advances toward clinical development in the United States, given the collaboration’s focus on IND-enabling manufacturing workflows.
Market Expansion: How this partnership positions Cellares in the Asia-Pacific region and its potential to attract additional collaborations in gene therapy manufacturing.